In China, the only access to HPV vaccine was delisted in the United States – Sohu health-sexhu

In China, the only access to HPV vaccine was delisted in the United States? Sohu health day ago, foreign pharmaceutical professional website Fierce Pharma broke the British pharmaceutical giant GlaxoSmithKline (GSK)’s cervical cancer vaccine "Cervarix" withdrawn from the U.S. market, a move away from the China news just listed only 3 months. According to Glaxo spokesman said, because of "Cervarix" in the United States market demand is very low, the company decided to withdraw from the US market. But this decision made us HPV Merck vaccine market "Gardasil" alone big situation. Sales slump in the Cervarix market is not back in the United States according to the U.S. Centers for Disease Control and Prevention (CDC) data, is expected to have 17 thousand women and a total of 9 thousand men due to HPV carcinogenic. In the United States, people have the HPV vaccine for choice: GlaxoSmithKline Co Cervarix, 2009 approved by FDA for women aged 10-25, 16, 18 and two can prevent HPV virus; 2006 Merck quadrivalent vaccine approved for the prevention of "Gardasil", 6, 11, 16, 18 and four subtypes of HPV; in December 2014, silent Merck launched "Gardasil 9", which is based on the original four newly added on the 31, 33, 45, 52 and 58 of the five subtypes of HPV, more than two kinds of vaccine Merck are suitable for men and women. Whether it is the global market share or the U.S. market, Merck "Gardasil" sales seem to be way ahead. According to WHO Miloud Kaddar "global vaccine characteristics and trend of" shows that in 2010 global sales of the best vaccine, Merck "Gardasil" on the list, global sales of $1 billion 350 million; in the first half of 2012 global vaccine sales summary, Merck’s "Gardasil" for $60 million 800 thousand, ranked third, only "Cervarix" $28 million 500 thousand, ranking eighth. Last year, Merck "Gardasil" global sales have reached $190 million; "Cervarix" in the global sales of $135 million, of which the United States market is about $5 million, less than 4%; the first half of 2016, "Cervarix" of the global sales of $48 million, total sales of $1 million in the U.S. market share has dropped to about 2%. The current downturn in sales, GlaxoSmithKline, explain the relevant person in charge, which is affected by the United States public health policy, Never mind and product coverage of the virus. Vaccination campaign out of public health policy? According to CDC data, the United States is expected to have 1.相关的主题文章: